

## Special Issue

# SARS-CoV-2: Immunopeptidomics and Other Immunological Studies

### Message from the Guest Editors

It is time to welcome contributions for this Special Issue titled “SARS-CoV-2: Immunopeptidomics and Other Immunological Studies.” The goal is to provide comprehensive information on all aspects of research related to the immunological studies of SARS-CoV-2 and immunopeptidomics for vaccine development. This Special Issue seeks all types of manuscripts (e.g., reviews, research articles, short communications) on immunopeptidomics and other immunological studies regarding SARS-CoV-2. We welcome the submission of both basic and applied research papers that aim to improve the understanding of the immune response against SARS-CoV-2, as well as the short- and long-term effects of host immune responses to SARS-CoV-2. We cordially invite you to contribute to this Special Issue to advance our knowledge of SARS-CoV-2 and to discover together the means to overcome the pandemic. This Special Issue is especially dedicated for the 75th Year celebration of L M College of Pharmacy, Ahmedabad (India).

### Guest Editors

Prof. Dr. Elrashdy M. Redwan

Biological Science Department, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia

Dr. Vivek P. Chavda

Department of Pharmaceutics and Pharmaceutical Technology, L M College of Pharmacy, Ahmedabad 380008, Gujarat, India

### Deadline for manuscript submissions

closed (31 May 2023)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/123821](https://mdpi.com/si/123821)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).